Open AccessJournal Article
The effects of subcutaneous deferoxamine administration on renal function in thalassemia major.
Reads0
Chats0
TLDR
There was a significant increase in urine volume during DFO therapy and these changes are consistent with the previous observation in humans and dogs receiving high dose i.v. DFO, albeit milder.Abstract:
To assess the effects of deferoxamine (DFO) on the kidneys, we studied 27 patients with thalassemia major on chronic subcutaneous (s.c.) DFO therapy. In 41% of the patients glomerular filtration rate (GFR) values were above the normal range. In a previous study similar findings were reported for thalassemia patients who did not receive DFO. The subcutaneous administration of DFO was associated with a clinically significant decrease in GFR in 40% of the patients and in a mild decrease in another 40%. In all cases of severe decreases in GFR, it tended to return to baseline values upon discontinuation of DFO. There was a significant increase in urine volume during DFO therapy. These changes are consistent with our previous observation in humans and dogs receiving high dose i.v. DFO, albeit milder.read more
Citations
More filters
Journal ArticleDOI
Iron-chelating therapy and the treatment of thalassemia
TL;DR: The toxicity of this agent mandates a careful evaluation of the balance between risk and benefit of deferiprone in patients with thalassemia, in most of whom long-term deferoxamine is safe and efficacious therapy.
Journal ArticleDOI
Practical management of iron overload
TL;DR: The ability to estimate the distribution of excess tissue iron, to predict its consequences and therefore to tailor treatment accordingly is surprisingly imprecise and the safest and most effective ways of removing excess iron vary depending on the degree and rate of iron loading as well as the underlying condition being treated.
Journal ArticleDOI
Secondary Iron Overload
TL;DR: The use of iron chelating agents in the management of transfusion-induced secondary iron overload is reviewed and guidelines are suggested for chelation therapy of chronically transfused adults with refractory anemias.
Journal ArticleDOI
Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial.
Aurelio Maggio,Gennaro D'Amico,Alberto Morabito,Marcello Capra,C. Ciaccio,Paolo Cianciulli,Felicia Di Gregorio,Giovanni Garozzo,R. Malizia,Carmelo Magnano,A Mangiagli,Giovanni Quarta,Michele Rizzo,Domenico Giuseppe D'Ascola,Aroldo Rizzo,Massimo Midiri +15 more
TL;DR: It is suggested that deferiprone may be as effective as deferoxamine in the treatment of thalassemia major with few mild and reversible side effects.
Journal ArticleDOI
Renal function in pediatric patients with beta-thalassemia major.
B. Aldudak,A. Karabay Bayazit,Aytül Noyan,Ozel A,Ali Anarat,I. Sasmaz,Yurdanur Kilinç,E. Gali,R. Anarat,Nurten Dikmen +9 more
TL;DR: The presence of high UP/Cr, UNAG/Cr and UMDA/Cr ratios shows that in these patients with proximal renal tubular damage may be secondary to oxidative lipid peroxidation mediated by the iron overload.
Related Papers (5)
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.
Maria Domenica Cappellini,Alan R. Cohen,Antonio Piga,Mohamed Bejaoui,Silverio Perrotta,Leyla Agaoglu,Yesim Aydinok,Antonis Kattamis,Yurdanur Kilinç,John B. Porter,Marcello Capra,Renzo Galanello,Slaheddine Fattoum,Guillermo Drelichman,Carmelo Magnano,Mônica Pinheiro de Almeida Veríssimo,Miranda Athanassiou-Metaxa,Patricia J. Giardina,Alexandra Kourakli-Symeonidis,Gritta Janka-Schaub,Thomas D. Coates,Christiane Vermylen,Nancy F. Olivieri,Isabelle Thuret,Herbert Opitz,C. Ressayre-Djaffer,Peter W. Marks,Daniele Alberti +27 more